DK3880654T3 - 2-formyl-3-hydroxyphenyloxymethylforbindelse som er i stand til at modulere hæmoglobin - Google Patents

2-formyl-3-hydroxyphenyloxymethylforbindelse som er i stand til at modulere hæmoglobin Download PDF

Info

Publication number
DK3880654T3
DK3880654T3 DK19818401.2T DK19818401T DK3880654T3 DK 3880654 T3 DK3880654 T3 DK 3880654T3 DK 19818401 T DK19818401 T DK 19818401T DK 3880654 T3 DK3880654 T3 DK 3880654T3
Authority
DK
Denmark
Prior art keywords
hydroxyphenyloxymethyl
hemoglobin
formyl
modulate
compound
Prior art date
Application number
DK19818401.2T
Other languages
English (en)
Inventor
Zhe Li
Original Assignee
Global Blood Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Blood Therapeutics Inc filed Critical Global Blood Therapeutics Inc
Application granted granted Critical
Publication of DK3880654T3 publication Critical patent/DK3880654T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
DK19818401.2T 2018-11-19 2019-11-18 2-formyl-3-hydroxyphenyloxymethylforbindelse som er i stand til at modulere hæmoglobin DK3880654T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862769196P 2018-11-19 2018-11-19
US201962821314P 2019-03-20 2019-03-20
US201962848773P 2019-05-16 2019-05-16
US201962883313P 2019-08-06 2019-08-06
PCT/US2019/062054 WO2020106642A1 (en) 2018-11-19 2019-11-18 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin

Publications (1)

Publication Number Publication Date
DK3880654T3 true DK3880654T3 (da) 2022-03-07

Family

ID=68848454

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19818401.2T DK3880654T3 (da) 2018-11-19 2019-11-18 2-formyl-3-hydroxyphenyloxymethylforbindelse som er i stand til at modulere hæmoglobin

Country Status (29)

Country Link
US (4) US10683285B2 (da)
EP (2) EP3880654B1 (da)
JP (1) JP7509772B2 (da)
KR (1) KR102842589B1 (da)
CN (1) CN113316568B (da)
AU (1) AU2019383960B2 (da)
BR (1) BR112021007044B1 (da)
CA (1) CA3120380A1 (da)
CO (1) CO2021007993A2 (da)
CR (1) CR20210335A (da)
CY (1) CY1125025T1 (da)
DK (1) DK3880654T3 (da)
ES (1) ES2908325T3 (da)
HR (1) HRP20220295T1 (da)
HU (1) HUE057323T2 (da)
IL (1) IL283128B2 (da)
LT (1) LT3880654T (da)
MA (1) MA54231B1 (da)
MD (1) MD3880654T2 (da)
MX (1) MX2021005887A (da)
PL (1) PL3880654T3 (da)
PT (1) PT3880654T (da)
RS (1) RS62970B1 (da)
SA (1) SA521422031B1 (da)
SG (1) SG11202104705RA (da)
SI (1) SI3880654T1 (da)
SM (1) SMT202200106T1 (da)
TW (1) TWI841630B (da)
WO (1) WO2020106642A1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015021982B1 (pt) 2013-03-15 2022-12-13 Global Blood Therapeutics, Inc Compostos e seus usos para a modulação de hemoglobina
KR102280614B1 (ko) 2013-03-15 2021-07-21 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
AU2014237330A1 (en) 2013-03-15 2015-09-17 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
SI3102208T2 (sl) 2014-02-07 2024-10-30 Global Blood Therapeutics, Inc. Kristalinični polimorf proste baze 2-hidroksi-6-((2-(1-izopropil-1H-pirazol-5-IL)piridin-3-IL)metoksi)- benzaldehida
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
EP3680241A1 (en) 2017-03-20 2020-07-15 Forma Therapeutics, Inc. Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
US10675274B2 (en) 2018-09-19 2020-06-09 Forma Therapeutics, Inc. Activating pyruvate kinase R
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
EP3860975B1 (en) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
JP7509772B2 (ja) * 2018-11-19 2024-07-02 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンのモジュレーター
HUE072832T2 (hu) 2019-09-19 2025-12-28 Novo Nordisk Healthcare Ag Piruvát kináz R-t (PKR) aktiváló készítmények
CA3176429A1 (en) * 2020-03-31 2021-10-07 Global Blood Therapeutics, Inc. Modulators of hemoglobin
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
JP2024520896A (ja) * 2021-05-14 2024-05-27 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンのモジュレーターを作製する方法
TW202311254A (zh) * 2021-05-14 2023-03-16 美商全球血液治療公司 血紅素之調節劑之固態形式
WO2023003332A1 (ko) 2021-07-19 2023-01-26 주식회사 바이오앱 식물 기반 covid-19 변이 재조합 스파이크 단백질 발현 벡터 및 상기 발현 벡터를 이용한 재조합 단백질
IL312835A (en) * 2021-12-10 2024-07-01 Global Blood Therapeutics Inc Methods for administering a hemoglobin modulator
TW202515579A (zh) 2023-06-13 2025-04-16 美商全球血液治療公司 投予血紅素的調節劑之方法
WO2025262596A1 (en) * 2024-06-20 2025-12-26 Pfizer Inc. Methods of making osivelotor

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
EP0022229B1 (en) 1979-06-29 1982-12-08 The Wellcome Foundation Limited Substituted phenol ethers, their preparation, intermediates therefor, pharmaceutical compositions containing them and the preparation thereof
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
GR76950B (da) 1980-12-18 1984-09-04 Wellcome Found
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
JPS63258463A (ja) 1987-04-14 1988-10-25 Kumiai Chem Ind Co Ltd ２−フエノキシピリミジン誘導体及び除草剤
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
EP0658559A1 (de) 1993-12-14 1995-06-21 Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. Thienothiazinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als 5-dipoxygenase und Cyclooxygenaseinhibitoren
HK1043106A1 (zh) 1998-12-14 2002-09-06 F. Hoffmann-La Roche Ag 苯基甘氨酸衍生物
CZ20013469A3 (cs) 1999-03-31 2002-04-17 Basf Aktiengesellschaft Diamidy pyridin-2,3-dikarboxylových kyselin
PL375532A1 (en) 2002-08-08 2005-11-28 Smithkline Beecham Corporation Benzimidazol-1-yl-thiophene compounds for the treatment of cancer
EP1567490B1 (en) 2002-12-04 2011-10-05 Virginia Commonwealth University Anti-sickling agents
RU2337908C2 (ru) 2003-06-12 2008-11-10 Ново Нордиск А/С Пиридинилкарбаматы в качестве ингибиторов гормон-чувствительной липазы
US7847120B2 (en) 2004-04-22 2010-12-07 Virginia Commonwealth University Intellectual Property Foundation Compositions of allosteric hemoglobin modifiers and methods of making the same
NZ564759A (en) 2005-06-30 2011-08-26 Prosidion Ltd GPCR agonists
CN100562514C (zh) 2005-07-22 2009-11-25 中国科学院上海药物研究所 一类取代丙酰胺衍生物、其制备方法和用途
TW200835687A (en) 2006-11-30 2008-09-01 R Tech Ueno Ltd Thiazole derivatives and their use as VAP-1 inhibitor
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
EP2271341B1 (en) 2008-05-08 2016-08-17 Nova Southeastern University Specific inhibitors for vascular endothelial growth factor receptors
GB0811451D0 (en) 2008-06-20 2008-07-30 Syngenta Participations Ag Novel microbiocides
TW201033201A (en) 2009-02-19 2010-09-16 Hoffmann La Roche Isoxazole-isoxazole and isoxazole-isothiazole derivatives
DK3738434T3 (da) 2011-12-28 2023-12-04 Global Blood Therapeutics Inc Mellemprodukter til opnåelse af substituerede benzaldehydforbindelser og fremgangsmåder til anvendelse deraf ved øgning af vævsoxygenering
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
BR112015021982B1 (pt) * 2013-03-15 2022-12-13 Global Blood Therapeutics, Inc Compostos e seus usos para a modulação de hemoglobina
KR102280614B1 (ko) 2013-03-15 2021-07-21 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AU2014237361A1 (en) * 2013-03-15 2015-09-17 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US20140271591A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compositions and methods for the modulation of hemoglobin (s)
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20150057251A1 (en) 2013-08-26 2015-02-26 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2015031284A1 (en) 2013-08-26 2015-03-05 Global Blood Therapeutics, Inc. Formulations comprising wetting agents and compounds for the modulation of hemoglobin (s)
US20160207904A1 (en) 2013-08-27 2016-07-21 Global Blood Therapeutics, Inc. Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US20150141465A1 (en) 2013-11-18 2015-05-21 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9248199B2 (en) 2014-01-29 2016-02-02 Global Blood Therapeutics, Inc. 1:1 adducts of sickle hemoglobin
SI3102208T2 (sl) 2014-02-07 2024-10-30 Global Blood Therapeutics, Inc. Kristalinični polimorf proste baze 2-hidroksi-6-((2-(1-izopropil-1H-pirazol-5-IL)piridin-3-IL)metoksi)- benzaldehida
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
AR108435A1 (es) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
JP7509772B2 (ja) * 2018-11-19 2024-07-02 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンのモジュレーター

Also Published As

Publication number Publication date
US20210047309A1 (en) 2021-02-18
ES2908325T3 (es) 2022-04-28
EP4046988A1 (en) 2022-08-24
US20230159507A1 (en) 2023-05-25
MD3880654T2 (ro) 2022-05-31
US11548880B2 (en) 2023-01-10
MA54231B1 (fr) 2021-12-31
IL283128B1 (en) 2024-11-01
MA54231A (fr) 2021-09-22
CA3120380A1 (en) 2020-05-28
KR102842589B1 (ko) 2025-08-04
EP3880654B1 (en) 2021-12-29
TW202039460A (zh) 2020-11-01
IL283128B2 (en) 2025-03-01
CN113316568B (zh) 2024-11-08
SG11202104705RA (en) 2021-06-29
JP7509772B2 (ja) 2024-07-02
US20260103454A1 (en) 2026-04-16
LT3880654T (lt) 2022-02-25
MX2021005887A (es) 2021-09-14
HUE057323T2 (hu) 2022-04-28
PL3880654T3 (pl) 2022-04-25
US20200157085A1 (en) 2020-05-21
TWI841630B (zh) 2024-05-11
BR112021007044B1 (pt) 2022-04-19
PT3880654T (pt) 2022-04-08
BR112021007044A2 (pt) 2021-07-27
WO2020106642A1 (en) 2020-05-28
EP3880654A1 (en) 2021-09-22
AU2019383960B2 (en) 2024-10-10
JP2022509091A (ja) 2022-01-20
AU2019383960A1 (en) 2021-06-10
SA521422031B1 (ar) 2023-12-24
SMT202200106T1 (it) 2022-05-12
CO2021007993A2 (es) 2021-06-30
SI3880654T1 (sl) 2022-04-29
WO2020106642A8 (en) 2020-12-30
IL283128A (en) 2021-06-30
KR20210093990A (ko) 2021-07-28
CR20210335A (es) 2021-09-14
RS62970B1 (sr) 2022-03-31
HRP20220295T1 (hr) 2022-05-13
CY1125025T1 (el) 2023-03-24
US10683285B2 (en) 2020-06-16
CN113316568A (zh) 2021-08-27

Similar Documents

Publication Publication Date Title
PL3880654T3 (pl) Związki 2-formylo-3-hydroksyfenyloksymetylowe zdolne do modulowania hemoglobiny
DK3774791T3 (da) Heterocykliske forbindelser som immunmodulatorer
DK3788040T3 (da) Pyridazinoner som parp7-inhibitorer
DK3873903T3 (da) Substituerede 6-azabenzimidazolforbindelser som hpk1-hæmmere
DK4219492T3 (da) Heterocykliske forbindelser som immunmodulatorer
DK3697785T3 (da) Imidazo-pyridine forbindelser som pad-inhibitorer
DK3277677T3 (da) 1-cyano-pyrrolidinforbindelser som usp30-hæmmere
MA49701A (fr) Composés immunomodulateurs
IL255313A0 (en) Solid forms of a compound modulating kinases
DK3768674T3 (da) Aminopyrimidinderivater som ctps1-hæmmere
DK3580220T3 (da) Aminotriazolpyridiner som kinasehæmmere
DK3532486T3 (da) Antistof-forbundne cykliske peptidtyrosin-tyrosinforbindelser som modulatorer af neuropeptid-y- receptorer
SI3743406T1 (sl) Modulatorji TMEM16A
DK3394033T3 (da) Heterocykliske forbindelser som immunmodulatorer
IL283967A (en) Modulators of hsd17b13 expression
DK3294713T3 (da) Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer
MA43512A (fr) Composés hétérocycliques utiles en tant que modulateurs du tnf alpha
DK3130592T3 (da) ANALOGER AF 4H-PYRAZOLO[1,5-á]BENZIMIDAZOL-FORBINDELSER SOM PARPINHIBITORER
IL281492A (en) Modulators of pnpla3 expression
DK3498278T3 (da) Forbindelser til behandling af sygdomme relateret til DUX4-ekspression
DK3233843T3 (da) Isoxazol-hydraxamsyreforbindelser som LPXC-hæmmere
DK3704118T3 (da) Aminoimidazopyrazin som kinasehæmmere
DK3625222T3 (da) Phenylderivater som pge2-receptormodulatorer
DK3717488T3 (da) Substituerede furanopyrimidinforbindelser som pde1-inhibitorer
DK3681885T3 (da) Tetrahydro-imidazo-quinolinsammensætninger som cbp/p300-inhibitorer